A Phase 1, Randomized, Double-Blind, Third-Party Open, Placebo-Controlled, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability, Immunogenicity, and Pharmacodynamics Following Intravenous Dose of PF-07275315 in Chinese Healthy Adult Participants
Latest Information Update: 11 Nov 2024
Price :
$35 *
At a glance
- Drugs PF-07275315 (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Pfizer
- 11 Nov 2024 New trial record